• Journal of Veterinary Clinics
• /
• v.39 no.5
• /
• pp.226-234
• /
• 2022

To evaluate butorphanol and tramadol as adjuvants to lidocaine in dogs undergoing mandibular nerve block. Fifteen beagles were allocated to groups based on the following treatments: lidocaine alone (L group), lidocaine + butorphanol (LB group), or lidocaine + tramadol (LT group). After mandibular nerve block with opioids as an adjunct to local anesthetics, the onset time, duration of action, and depth of anesthesia were evaluated using a quantitative method through neuromuscular blockades (NMBs) monitoring. The onset time of nerve block was 4.60 ± 2.06 min, 2.00 ± 0.00 min, and 2.60 ± 1.62 min in the L, LB, and LT groups, respectively; however, there was no statistically significant difference. The duration of nerve block was 111.88 ± 34.78 min, 302.00 ± 76.72 min, and 260.40 ± 49.88 min in the L, LB, and LT groups, respectively, with a significant difference between L and LB groups. The LB group demonstrated a more profound depth of anesthesia compared to the L and LT groups. In this study, using a quantitative method through NMBs monitoring, it was demonstrated that lidocaine and butorphanol in combination can increase the duration of nerve block and more profound the depth of anesthesia rather than lidocaine alone. Additionally, the combined use of lidocaine and opioids presented an objective indicator that could provide a more clinically stable nerve block.

• Journal of Veterinary Clinics
• /
• v.30 no.6
• /
• pp.421-427
• /
• 2013

There are many intramuscularly injectable drugs commonly used for anesthesia in dogs and combination of drugs were used for decrease the side effects. The objective of this study was to evaluate the anesthetic and cardiopulmonary effects of butorphanol-tiletamine-zolazepam-medetomidine and tramadol-tiletamine-zolazepam-medetomidine in dogs. Ten healthy beagle dogs (intact male; mean body weight : $9.5{\pm}1.60$ kg) were used in the study. Experimental animals were divided into two groups (n=5, each) and received 0.2 mg/kg of butorphanol (BZM) and 2 mg/kg of tramadol (TZM) according to the group after injection of $Zoletil^{(R)}$ (5 mg/kg) and medetomidine (10 ug/kg). All drugs were administered intramuscularly. Anesthesia and recovery, sedation and analgesia score, cardiovascular and respiratory parameters were measured. Induction and recovery time were not significantly different between the groups. Anesthesia time was $117.4{\pm}25.64$ minute and $81.2{\pm}12.50$ minute in BZM and TZM groups, respectively. Sedation and analgesia were satisfied in both groups. In both groups, common side effects related to the medetomidine, significant bradycardia and hypertension were not observed. There were no significant changes in respiratory data. In conclusion, tiletamine-zolazepam-medetomidine in combination with either butorphanol or tramadol can be suitable anesthetic protocol for minor procedures in dogs. They produced adequate anesthesia characterized by rapid induction, adequate analgesia and muscle relaxation without remarkable side effects.

• Journal of Veterinary Clinics
• /
• v.24 no.3
• /
• pp.419-421
• /
• 2007

A 15 years old castrated male Pug dog was referred with chief complaint of cough, described as a goose honk. He was diagnosed into of tracheal collapse by clinical signs and radiography. He was received by injection- AP with butorphanol (0.15 mg/kg, SID) at BL13, LU01, LU05, LU06, LU07, LU09 and CV22 for 10 days, and he was also received by injection-AP with butorphanol (0.40 mg/kg, SID) at BL13, LU01 and CV22 for 9 days. The patient was given with Sochungryong-Tang (0.5 g/head, TID) for 7 days, and he was additionally given with Sojagangki-Tang (1 ml/kg, TID) for 12 days. Cough was not detected at all, and tracheal diameter was more increased than that of session 1 on radiograph at session 19. Cough was not detected at all and tracheal diameter at follow-up study of three month later was more dilated than that of session 19. In conclusion, the present patient was a case with canine tracheal collapse which showed favorable therapeutic response by injection-AP with butorphanol combined by administration of herbal medicine.

• The Korean Journal of Pain
• /
• v.14 no.1
• /
• pp.46-50
• /
• 2001

Background: Ondansetron is both a central and peripheral serotonin (5HT) receptor antagonist and droperidol is a dopaminergic blocking drug which acts centrally at the chemoreceptor trigger zone. We assessed the efficacy and adverse effects of ondansetron, droperidol or both, in the prevention of postoperative emesis during postoperative intravenous patient-controlled analgesia (PCA) using butorphanol and ketorolac medication. Methods: We studied 60 women, aged 25-60 yrs, who underwent total abdominal hysterectomy (TAH), under general anesthesia using $N_2O-O_2$-enflurane. A bolus dose of 1 mg of butorphanol and 4 mg of ondansetron were given to patients and thereafter, PCA was started using 10 mg of butorphanol and 240 mg of ketorolac mixed into the 5% D/W solution (total volume; 100 ml, 1 ml of bolus dose, and 10 min of lockout interval). We also added ondansetron 4 mg (Group O, n = 20), ondansetron 4 mg and droperidol 2.5 mg (Group OD, n = 20), or droperidol 2.5 mg (Group D, n = 20) to the PCA drug. The severity of pain, nausea, vomiting, sedation and other side effects were assessed at 0, 1, 2, 6, 12, 24, 36 and 48 hr after awakening. Results: There was no difference in the incidence of nausea and vomiting between the three group [Group O: 4 (20%) and 3 (15%), respectively; Group OD: 1 (5%) and 1 (5%), respectively; Group D: 3 (15%) and 3 (15%), respectively]. Group O showed a lower sedation score than the other groups (P < 0.05). The pain score and other side effects did not show any difference between the groups. Conclusions: The combination of ondansetron and droperidol showed no clinical benefit compared with ondansetron or droperidol alone for prevention of postoperative nausea and vomiting during postoperative PCA using butorphanol and ketorolac.

• Journal of Pharmaceutical Investigation
• /
• v.32 no.1
• /
• pp.1-6
• /
• 2002

The mucoadhesive characteristics of [P(AA-co-PEGMM)] films by estimating the glass transition temperature $(T_g)$, analyzing surface energy and studying FT-IR was previously reported. In this study, the possibility of buccal mucoadhesive dosage form of [P(AA-co-PEGMM)] films by mucoadhesive force measurements and dissolution tests were also investigated. Mucoadhesiveness of [P(AA-co-PEGMM)] films was compared with cr-PAA and cr-PEGMM films crosslinked with 3% ethyleneglycol dimethacrylate (EGDMA). The buccal mucoadhesive force of [P(AA-co-PEGMM)] films increased with increasing content of PEGMM. [P{AA-co-PEGMM (18 mole%)}] films showed a significantly greater mucoadhesiveness than cr-PAA and cr-PEGMM films. The mucoadhesive force measured in normal saline (pH 5.0) was higher than that measured in phosphate buffer (pH 6.8) because of the pH dependence of hydrogels with carboxyl ions within the PAA. Moreover, the mucoadhesive force of [P{AA-co-PEGMM (18 mole%)}] films was at maximum after 2 hr attachment of buccal mocosa and it was maintained over $1\;N/cm^2$ for up to 10 hr. In dissolution studies, the release of butorphanol tartrate from [P(AA-co-PEGMM)] films increased with increasing PEGMM content, and films prepared with 18 mole% PEGMM gave almost zero order release kinetics.

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2007.05a
• /
• pp.133-133
• /
• 2007

• Journal of Veterinary Clinics
• /
• v.27 no.6
• /
• pp.674-678
• /
• 2010

The effects of medetomidine on the degree of analgesia and sedation in rats were evaluated. The rats were randomly divided into six groups: saline, 1 mL/kg (group 'Saline'); butorphanol, 2.0 mg/kg; medetomidine, 0.2, 0.4, 0.8 or 1.6 mg/kg (group 'MED0.2', 'MED0.4', 'MED0.8' and 'MED1.6', respectively). The degree of analgesia was measured in the $50^{\circ}C$ hot-water tail-flick latency test, and the degree of sedation was evaluated using the numerical sedation score (NSS) and the righting reflex. All doses of medetomidine, except MED0.2, significantly increased the analgesic effect compared to the Saline group. Variables in the MED0.4 and MED0.8 groups, but not in the MED1.6 group, were significantly increased compared to those in the MED0.2 group. However, analgesia with all doses of medetomidine was not significantly different compared to that with butorphanol. Saline and butorphanol treatments did not induce sedation and loss of righting reflex during the recording period. NSS in the MED0.4, MED0.8 and MED1.6 groups were significantly higher than that in the MED0.2 group. NSS in the MED0.8 and MED1.6 groups were not significantly different from that in the MED0.4 group. The latency to loss of righting reflex in the MED0.8 and MED1.6 groups decreased significantly compared to that in the MED0.2 group. Thus, 0.4 and 0.8 mg/kg of medetomidine provided not only reliable analgesia but also sedation to rats. In conclusion, 0.4 to 0.8 mg/kg medetomidine could be a useful chemical restraint method in rats.

• Journal of Veterinary Clinics
• /
• v.31 no.4
• /
• pp.350-353
• /
• 2014

A 13-year-old, castrated male, Shih Tzu dog with a history of acute ataxia was referred to veterinary medical teaching hospital and anesthetized for diagnostic magnetic resonance imaging of cervical intervertebral disk disease. After preanesthetic evaluation including physical examination, blood chemistry, radiography and ultrasound, the patient was premedicated with intravenous butorphanol (0.2 mg/kg). Anesthesia was induced by intravenous propofol (6 mg/kg) and maintained with isoflurane at 1.2 minimal alveolar concentrations. Because the mean arterial pressure (MAP) decreased from 70 to 58 mmHg at 70 minutes after induction, dobutamine was administered by constant rate infusion ($5{\mu}g/kg/min$) to treat hypotension. However MAP did not increase, and heart rate rapidly decreased from 100 to 55 beats per minute (bpm). To treat bradycardia, intravenous glycopyrrolate ($5{\mu}g/kg$) was administered, and heart rate increased to 165 bpm. After extubation of endotracheal tube, the patient showed normal recovery without any problems related to cardiovascular system. Unexpected dobutamine-induced bradycardia was considered as Bezold-Jarisch reflex. It is recommended that clinicians know and prepare the possibility of bradycardia during dobutamine therapy under general anesthesia.

• Journal of Veterinary Clinics
• /
• v.28 no.1
• /
• pp.40-45
• /
• 2011

Cardiovascular changes caused by $CO_2$ pneumoperitoneum during laparoscopic ovariohysterectomy (LOVH) were measured in nine healthy mixed breed dogs ($16.7{\pm}4.6kg$). The dogs were premedicated with the combination of atropine, acepromazine, and butorphanol. General anesthesia was induced with propofol and maintained with isoflurane in oxygen. Controlled ventilation maintained partial pressure of end-tidal $CO_2$ between 35-45 mmHg. The $CO_2$ pneumoperitoneum was maintained at a constant pressure of 12 mmHg and the dog was placed in the $15^{\circ}$ Trendelenburg position as LOVH was performed. Dorsal pedal artery was catheterized for measurements of heart rate (HR) and invasive arterial blood pressure (IBP). Prior to the intraperitoneal insufflation, baseline measurements of HR and IBP were made every minute for a total of 10 min. Then, measurements of HR and IBP were made every 5 min following intraperitoneal insufflation and were also made every 5 min following desufflation for a total of 10 min. The $CO_2$ pneumoperitoneum during LOVH resulted in a significant (P < 0.05) increase in systolic arterial blood pressure at the time of the onset of insufflation. In addition, diastolic and mean arterial blood pressure increased significantly (P < 0.05) at the time of the onset of insufflation and 5 min following insufflation. The mean heart rate did not change significantly during LOVH. Although IBP showed sharp initial rise following the $CO_2$ pneumoperitoneum, the changes were within physiological acceptable limits in these healthy, ventilated dogs.